I believe the odds are still pretty good for Oncosec once the data for PISCES and also TNBC is mature. Algazi said the 1 PD patient is expected to become a responder in the PISCES trial....so that would put us at 33% response rate.
These patients received just a single cycle of TAVO per protocol, not a full regimen. There may be others - like the two who went straight to pembro and responded - who went off protocol, but I wouldn't count on it. The point of OMS140 was to view immunologic responses with a single cycle. I don't think they will look at BORR for OMS140.
News 
Market Data 
Discover 
